The lymphoid-speci®c protein tyrosine kinase, p56 lck which is essential for both T cell development and function, is aberrantly expressed in colon and small lung carcinoma lines. In this paper, we demonstrate p56 lck is also expressed in colon tumour biopsies due predominantly or exclusively to the use of the lck type I promoter. In T leukaemia lines, the lck type I promoter requires binding sites for both Ets-and Myb-related transcription factors. In contrast, in colon tumour lines the activation of the lck type I promoter requires the Ets but not the Myb binding site. In these lines, a consensus binding site for HMG-related transcription factors, AACAAAG, is required for ecient lck type I promoter activity. Sox-4 is a candidate transcription factor for binding and activating the lck type I promoter in colon carcinoma cells. Co-expression of Ets-1 and Sox-4, but neither protein alone, was sucient to activate the lck type I promoter in HeLa cells which do not normally express lck transcripts. These results suggest that aberrant expression of p56 lck from the lck type I promoter in colon carcinoma arises from transcriptional activation mediated by Ets-and HMG-related transcription factors.
Introduction
The lck gene encodes the src family tyrosine kinase, p56 lck which plays an important role in T cell signal transduction pathways by virtue of its association with cell surface glycoproteins, such as CD4 and CD8 coreceptors or the b subunit of the IL2 receptor (Bolen et al., 1992; Minami et al., 1993) . p56
lck is also required for T cell maturation since disruption of this gene or overexpression of a catalytically inactive mutant results in a block in the early stages of thymic maturation, causing thymic atrophy and a severely reduced T cell population (Molina et al., 1992; Levin et al., 1993) . T cell development in the absence of p56 lck expression is impaired at an immature CD4 7
CD8
7 stage, suggesting that lck function is important in the transition from CD4 7
7 to CD4 + CD8 + T cells. The pre-TCR, which plays an integral role in early T cell maturation, is believed to signal through p56 lck to induce the dierentiation to CD4 + CD8 + T cell stage (Groettrup and von Boehmer, 1993; Mombaerts et al., 1994; Fehling et al., 1995) . Expression of p56 lck is normally restricted to lymphoid cells, with high levels of expression in thymocytes and T cells, and lower levels of expression in B and NK cells (Bolen et al., 1992) . Two promoters are responsible for transcription of the lck gene: the proximal or type I promoter produces type I transcripts and the distal or type II promoter produces type II transcripts (Takadera et al., 1989; Reynolds et al., 1990; Leung and Miyamoto, 1991; Wildin et al., 1991) . The type I and II transcripts dier only in their 5' untranslated regions. In immature thymocytes both promoters are used, while in mature thymocytes and T cells lck transcription is almost exclusively from the type II promoter. The level of p56 lck in thymic ontogeny appears to be critical since overexpression of lck results in delayed thymocyte development and tumorigenesis (Abraham et al., 1991a,b) . Hence, the activity of the lck type I and II promoters must be tightly regulated in T cells.
The lck gene is aberrantly expressed in human colon and small cell lung carcinomas. In these lines lck transcripts are derived exclusively from the type I promoter Sartor et al., 1989; Leung and Miyamoto, 1991) . The role of p56 lck in these cells is not known, however, comparison of the colon carcinoma lines SW620 and SW480 and its variants, which express variable levels of lck transcripts and protein, suggests that p56 lck may be associated with a more aggressive behaviour Trainer et al., 1988) . Based on these observations, it is important to understand the mechanism by which the lck gene is activated in non-lymphoid malignancies.
We have previously shown that both appropriate and aberrant expression of lck type I transcripts in Jurkat and SW620 cells, respectively, requires the presence of an Ets binding element (EBE) in the type I promoter, indicating that type I promoter activation by Ets factors is a common mechanism for both pathways of expression (Leung et al., 1993) . However, the activity of Ets-related transcription factors alone is not sucient to activate this promoter in Jurkat cells; in these cells Myb works in synergy with Ets factors to drive transcription from the lck type I promoter (McCracken et al., 1994 ).
Herein we demonstrate the expression of lck type I transcripts and p56 lck in both colon carcinoma lines and colon tumour biopsies. We show that the expression of the lck type I promoter in colon carcinoma cell lines arises largely from a mechanism of transcriptional activation that is not signi®cant in T leukaemia cell lines; this alternate pathway entails transcriptional activation of the type I promoter by an HMG-related transcription factor(s) expressed in certain colon carcinoma lines.
Results

Expression of lck in human colon carcinoma lines
Previous work by us and others demonstrated the expression of lck type I transcripts and p56 lck in cell lines derived from human colon and small cell lung carcinomas Sartor et al., 1989; Leung and Miyamoto, 1991) . To determine whether there might be a physiological role for p56 lck in colon carcinoma we looked for a correlation between the level of expression of p56 lck and the tumorigenic behaviour of colon carcinoma lines. SW620 and SW480 were derived from the same patient's lymph node metastases and primary colon tumour, respectively Trainer et al., 1988) . R2 and E8 are SW480 variants that were selected for growth with epithelial-like or rounded morphology, respectively (Tomita et al., 1992) . In nude mice, SW620 and SW480 R2 are highly tumorigenic, while SW480 is weakly tumorigenic and SW480 E8 is nontumorigenic. RT ± PCR and Western blotting analyses revealed that lck type I transcripts and p56 lck protein are more abundantly expressed in SW620 and SW480 R2 than in SW480 and SW480 E8 (Figure 1 ). Thus, in closely matched human colon carcinoma lines lck expression in vitro appears to correlate with tumorigenic or metastatic potential in vivo.
Expression of lck in primary colon tumours
To determine whether lck expression in colon carcinoma lines is an artifact of cell culture or occurs in vivo, we obtained tumour and normal adjacent tissue from six patients with colon carcinoma. RT ± PCR was used to identify lck type I transcripts in the paired biopsy samples. As shown in Figure 2 , we found strong expression of lck type I transcripts in the tumour tissue from three patients. No detectable lck type I transcripts were observed in normal tissue.
Lck protein expression in primary colon carcinoma and cell lines
As the colon tumours are in®ltrated by T lymphocytes it is possible though unlikely that the lck type I transcripts were derived from these cells. To demonstrate that lck expression was indeed present in the epithelial tumour cells we used immunohistochemical staining. As a control, we ®rst showed that the puri®ed anti-lck antibody speci®cally stains the cytoplasm of SW620 tumour cells grown in SCID mice (Figure 3a) . Sections from one of the RT ± PCR lck-positive primary adenocarcinoma specimens, were stained either with anity puri®ed anti-lck polyclonal antibody or an antibody that recognizes the T cell-speci®c CD3 antigen. Expression of p56 lck is evident in both T cells and tumour. In contrast, only the T-cells reacted with the anti-CD3 antibody (Figure 3b ). Adjacent samples of normal tissue from the same patient showed no p56 lck expression (data not shown). These results con®rm the expression of lck in primary tumours and support the suggestion that the presence of p56 lck protein arises from the aberrant expression of lck type I transcripts.
Regulatory elements important for lck type I promoter activity in colon carcinoma lines Previously we showed that the expression of the lck type I promoter in both Jurkat T leukaemia and SW620 colon carcinoma cell lines requires an Ets binding element (EBE) located at 797 to 790 (Leung et al., 1993) . In addition, in Jurkat cells a Myb binding site at 759 to 754 is required (McCracken et al., 1994) . To determine if this Myb site is also important in the regulation of lck in colon carcinoma we transfected into dierent T leukaemia and colon carcinoma lines, constructs consisting of a rabbit b-globin reporter gene driven by the human lck type I promoter containing the wild-type or a mutated form of the Myb binding site. Mutation of the Myb site resulted in a dramatic 90 ± 94% reduction in lck type I promoter activity in Jurkat and CEM T leukaemia cells; in contrast, only a modest 20 ± 30% decrease in lck type I promoter activity was observed in the colon carcinoma lines SW620 and Colo201 ( Figure 4 and Table 1 ). Con®rming our previous data, point mutation of the EBE inhibits lck type I promoter activity by at least 90% in both T leukaemia and colon carcinoma lines ( Figure 4 and Table 1 ). Ets proteins often work in synergy with other transcription factors, including Myb, Sp1 and CBF, to regulate transcription from several T cell-speci®c gene promoters (McCracken et al., 1994; GeÂ gonne et al., 1993; Wotton et al., 1994) . We thus hypothesized that another transcription factor, binding to the lck type I minimal promoter region, cooperates with Ets proteins to activate lck transcription in these colon carcinoma lines. We focused our attention to the region between the EBE and the Myb binding site, which contains the sequence AACAAAG located at 776 to 770 and corresponds to a consensus binding site for the sequence-speci®c members of the high mobility group (HMG) family of DNA binding proteins (Grosschedl et al., 1994) . Reporter constructs carrying dierent mutated versions of this HMG site were transfected into the T leukaemia and colon carcinoma lines. The mutants pLDB.A and pLDB.M contain base substitutions in the 5' and 3' sequence, respectively, of the HMG site (Table 1) . The HMG site mutation in pLDB.A resulted in a 70 ± 80% reduction in lck type I promoter activity in SW620 and Colo201 cells (Figure 4 ), whereas the HMG site mutation in pLDB.M resulted in only a modest 30% reduction in SW620 cells (Table 1) . To determine whether the HMG site is also important for T cell lck expression, the same constructs were transfected into Jurkat and CEM cells. pLDB.A retained 70 ± 100% of the wild-type lck type I promoter activity while pLDB.M retained 50% of wild-type activity ( Figure 4 and Table 1 ). This data suggests that a HMG protein(s), whose DNA recognition sequence includes the 5' portion of the HMG site, plays an important role in activation of the lck type I promoter in colon carcinoma but is not essential for lck expression in T cell lines.
Protein complexes on the HMG site
Having shown the importance of a functional HMG site for activation of lck transcription in colon carcinoma lines, we sought to determine whether there were proteins in these cells that could bind speci®cally to the lck type I promoter HMG site in vitro. We ®rst tested three known HMG proteins, Sox-4, TCF-1 and LEF-1, which have been shown to bind to the consensus HMG site (A/TA/TCAAAG) Leiden and Thompson, 1994) . To demonstrate the ability of HMG proteins to bind speci®cally to the HMG site in the lck type I promoter, Sox 4, TCF-1 and LEF-1 were expressed in bacteria and used in gel mobility shift assays. Each of these proteins bound eciently to radio-labelled double-stranded oligonucleotide spanning the wild-type HMG site (WT HMG ds oligo) ( Figure 5 ). We next carried out competition experiments to determine whether HMG ds oligos corresponding to the mutated HMG sites (A or M) could displace binding of Sox-4, TCF-1 or LEF-1 to the WT HMG ds oligo. Unlabelled WT, A and M HMG ds oligos were added to reactions containing radiolabelled WT HMG ds oligo and Sox 4, TCF-1 or LEF-1. As expected, the WT HMG ds oligo eciently competed in each case. The A HMG ds oligo eciently competed speci®c binding in reactions containing TCF-1 or LEF-1 but not Sox-4. Conversely, the M HMG ds oligo eciently competed speci®c binding in reactions containing Sox-4 but not TCF-1 or LEF-1. This indicates that Sox-4 does not bind eciently to the mutant A sequence, whereas TCF-1 and LEF-1 do not bind well to the mutant M sequence. This dierential anity is of value in trying to determine which of the HMG proteins may be acting within a particular cell type.
To determine whether proteins in colon carcinoma cells could bind to the lck type I promoter HMG site, nuclear extracts of SW620 and Jurkat were mixed with radiolabelled WT HMG ds oligo; unlabelled WT, A and M HMG ds oligos were used as competitors. Nuclear extracts from SW620 and Jurkat formed several complexes with the WT HMG ds oligo ( Figure 6 ). These complexes were eciently competed by unlabelled WT HMG ds oligo but not by a randomly mutated form of the HMG site (Pv HMG ds oligo). To determine whether the proteins in the speci®c complexes were more likely to be related to Sox-4 or TCF-1/LEF-1, competition experiments were performed with A and M HMG ds oligos. The M HMG ds oligo reduced all of the compelxes formed with SW620 nuclear extract, while the A HMG ds oligo had almost no eect. The M HMG ds oligo reduced the intensity of a fast moving J1 complex observed in Jurkat nuclear extracts. This suggests that all of these complexes are due to binding of Sox-4 or a Sox-4-related protein. The A HMG ds oligo had no eect on binding of SW620 nuclear extract proteins, while it did compete for formation of the slower moving complex J2 in Jurkat nuclear extracts.
Synergistic activation of the lck type I promoter by Ets-1 and Sox-4
Previously we found that Ets-1 and c-Myb synergistically activated the lck type I promoter in transfected HeLa cells, a cell type that does not normally express lck. To determine if similar synergism could be seen for Ets-1 and Sox-4, we performed co-transfection experiments in HeLa cells. All the reporter gene constructs, containing the lck type I promoter, wild-type (WT), Ets-2 in HeLa cells the ability of Sox-4 alone to activate lck type I expression can only be assessed in the context of an EBE mutant. This produces levels of lck type I transcripts not signi®cantly above background (data not shown). Therefore both Ets and Sox-4 related transcription factors are required for expression of the lck type I promoter. Thus, Ets-1 and Sox-4 can activate the lck type I promoter in HeLa cells; this activation requires the presence of functional Ets and HMG binding sites. This data supports the conclusion that expression of the lck type I promoter in colon carcinoma is driven by Ets-and Sox-4-related transcription factors.
Discussion
In this paper, we have demonstrated p56 lck , derived from lck type I transcripts, is expressed in colon carcinoma and colon tumours. The expression of lck type I transcripts and p56 lck in the colon carcinoma lines appears to correlate with their tumorigenic or metastatic potential in vivo. Since the lck gene does not appear to be expressed in normal colonic crypts (Siyanova et al., 1994) , and peripheral T lymphocytes express lck type I transcripts at barely detectable levels, lck type I transcripts identi®ed by RT ± PCR are likely to be tumour-speci®c.
We investigated the mechanisms of lck type I promoter activation in colon carcinoma lines and discovered a requirement for a dierent class of transcription factors than that in T cell leukaemia lines. In Jurkat and CEM cells, the expression of lck type I transcripts is driven by synergistic action of Etsand Myb-related transcription factors. However, in SW620 and Colo201 cells, transcriptional activation by c-Myb, which is expressed at very low or undetectable levels (McCracken, unpublished data), is not essential for lck type I promoter activity. Instead we identi®ed a HMG binding site which, in the presence of a functional Ets binding site, was important for transactivation of the lck type I promoter. The importance of this HMG binding site was demonstrated by transfection experiments and the ®nding of nuclear proteins in SW620 and Colo201 cells that could eciently bind to oligonucleotides containing the HMG site.
The HMG superfamily of DNA binding proteins consists of a subgroup of transcription factors which contain a single repeat of the DNA binding domain of the high mobility group proteins (HMG box), bind to DNA in the minor groove in a sequence-speci®c manner and bend DNA (Grosschedl et al., 1994) . The best characterized members of this subfamily are the lymphoid-speci®c transcription factors, LEF-1 and TCF-1, the sex-determination factor SRY, and the closely related Sox transcription factors . HMG proteins may function as architectural assembly factors in which protein-protein interactions can enhance the speci®c recruitment of proteins to their target sites. By perturbing the DNA architecture, bound trans-acting factors, which are widely separated, can physically and functionally interact with each other. In Using ds oligos containing wild-type or HMG site point mutations in the lck type I promoter and bacterially expressed Sox-4, TCF-1 and LEF-1, we found that the nucleotide sequences important for binding by Sox-4 dier from those important for the binding of TCF-1 and LEF-1. These mutated HMG binding sites proved useful in determining the relevant type of HMG protein involved in lck type I promoter transactivation. By transfection studies using mutant reporter gene constructs and competition studies in gel mobility shift assays it would appear that Sox-4, or a protein with similar binding speci®city, may be the relevant transcription factor, and that TCF-1 and LEF-1 do not play a signi®cant role in lck transactivation in colon carcinoma. RT ± PCR analysis of SW620 and Colo201 cells showed the presence of Sox-4 transcripts (data not shown). Unfortunately, Sox-4 speci®c antibodies that could be used in supershift or Western blotting analyses are not available to conclusively show that Sox-4 is involved in the regulation of lck in colon carcinoma.
Previously we showed that the ecient expression of the lck type I promoter in Jurkat T cells requires Ets-and Myb-related transcription factors. In this paper, we show that in colon carcinoma lines the ecient expression of the lck type I promoter requires Ets-and HMG-related transcription factors. Both cMyb and the HMG proteins require the action of an Ets-related transcription factor, since mutation of the EBE is sucient to abolish transcription. However, cMyb and HMG proteins are able to bind DNA independently, at least in vitro, suggesting that synergism with Ets proteins occurs post-DNA binding. The mechanism of activation of the lck type I promoter by Sox-4 or related proteins is not known at this time.
In summary, it appears that the induction of lck expression in colon carcinoma arises from the deregulation of the expression and/or activity of Ets-and HMGrelated transcription factors. This aberrant expression of lck may contribute to the malignant phenotype of colon tumours. Other src-related tyrosine kinases, p59 yes and p60 src have been reported to be up-regulated in colon carcinoma Cartwright et al., 1990; Park et al., 1993) . Dierent src family members could play distinct roles in colon tumour progression. It is also likely that genes other than lck are transcriptionally activated by the aberrant activity of Sox-4 or related proteins; these genes may also contribute to the malignant nature of the cell. It will be important to identify these other genes and determine their potential role in colorectal tumorigenesis.
Materials and methods
Cell culture
CEM and Jurkat cells were grown in suspension culture in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM glutamine, penicillin, and streptomycin. SW620 cells were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum, penicillin, and streptomycin. Colo201 and HeLa cells were grown in aMEM supplemented with 10% fetal bovine serum, penicillin, and streptomycin.
Western blots
1610
7 cells were washed three times in PBS prior to lysis in Laemmli sample buer. Total proteins were analysed by SDS ± PAGE and transferred to nitrocellulose using standard methods. Western blots were visualized using the ECL detection system from Amersham. Anti-p56 lck antiserum was used at 1/2000 dilution.
RT ± PCR analysis 0.5 mg of RNA from colon tumour biopsies or normal adjacent tissue was heated at 658C for 2 min, then quick chilled on ice and added to the following cDNA reaction mixture: 16reverse transcriptase buer, 0.5 units/ml of RNasin, 0.25 mM of dNTPs, 1 mM of DTT, 5 mM of Hexamer, and 100 units of MuMLV. This mixture was incubated at 238C for 10 min, 428C for 30 min, 958C for 5 min and then chilled on ice. The cDNA mixture was added to the following PCR mixture: 16PCR buer, DMSO, Taq polymerase, and primers. The primers were 0.2 mM of E2 (complementary to codon 7 to codon 16 in the lck coding sequence from +257 to +228), 0.1 mM of lck I (+30 to +59 in the human lck type I promoter), 0.1 mM of lck II (+66 to +95 in the human lck type II promoter) as described previously (Leung and Miyamoto, 1991) . The PCR was performed at 968C for 2 min, 648C for 1 min, and 728C for 1 min for 35 cycles. PCR products were then electrophoresed through an agarose gel followed by Southern blot analysis using a radiolabelled lck-speci®c probe.
Total RNA from cells in culture was analysed for lck type I and II transcript expression by RT ± PCR as described previously (Leung and Miyamoto, 1991) . As a loading control, RT ± PCR of b-actin transcripts was performed as above using a ®rst exon sense primer and second exon antisense primer. PCR products were electrophoresed through an agarose gel followed by Southern blot analysis using radiolabelled lck-and b-actin-speci®c probes.
Immunohistochemistry
Staining of frozen sections of SW620-induced tumours in SCID mice (a) Harris' Haematoxylin-Eosin Stain (Manual Method): Slides were heated at 608C for 20 min in a slide drier. The slides were then soaked in toluene for 5 min, rinsed sequentially with absolute, 95%, and 70% alcohol, and then H 2 O. The slides were stained in Harris' Haematoxylin for 5 min, rinsed with H 2 O, dierentiated in acid alcohol (HCl, 1 ml; 70% alcohol, 250 ml), rinsed with H 2 O, blued in ammonia H 2 O and rinsed in H 2 O or blued in warm H 2 O for 5 min. The slides were then dipped in 70% alcohol and stained in Eosin (0.5% eosin and 1% acetic acid) for 1 min, rinsed in H 2 O, dehydrated, cleared, and mounted with permount. The nuclei appears blue and the other tissue elements appear pink; (b) Anity puri®ed polyclonal rabbit a-lck: All slides were ®xed in 4% paraformaldehyde for 10 min at RT prior to staining. The slides were blocked ®rst with endogenous peroxidase in 0.3% H 2 O 2 /PBS and second with 5% normal goat serum; each block was for 10 min at RT with a ®nal wash in PBS. The anti-lck antibody (1/100 dilution, 50 ± 75 ml) was applied and incubated for 1 h at RT. Slides were prepared with two drops of biotinylated secondary and two drops of streptavidin-peroxidase from LSAB-2 kit sequentially with PBS washes and 20 min incubation at RT after each application. Slides were incubated in chromogen for 10 ± 20 min at RT, counter- Double staining of human colon tumour biopsy Slides were ®xed and blocked as described above. The ®rst antibody for CD3 (1/100 dilution, 50 ± 75 ml) and the second antibody for a-lck (1/100 dilution, 50 ± 75 ml) were applied sequentially. Following each antibody addition, the slides were incubated, prepared and counterstained as described above.
Plasmids and mutagenesis
The plasmids pLDB and pLDR, containing the MscIBamHI (7412 to +82) and RsaI-BamHI (7128 to +82) fragments, respectively, fused to the promoter-less rabbit b-globin reporter gene in pGb, were previously described (Leung et al., 1993) . Point mutations in pLDB and pLDR were generated by oligonucleotide mutagenesis in M13 , using the non-coding strand mutants oligonucleotides shown below, followed by insertion of the point mutated fragments into pGb (Leung et al., 1993) . The mutants oligos were as follows:
Transient transfections
The human lck type I promoter reporter gene plasmids were introduced into Jurkat and CEM cells (10 mg reporter, 1610 7 cells) using the DEAE-dextran procedure (Leung et al., 1993) . SW620 and Colo201 cells (5610 6 cells/100 mm dish) were transfected using calcium phosphate-DNA co-precipitation. 27.5 and 30 mg of reporter gene plasmid DNA was used in SW620 and Colo201 transfections, respectively. Co-transfections of 20 mg of reporter gene plasmid DNA and 5 mg of SV40-based expression vectors expressing chicken c-Ets-1 or human Sox-4 were introduced into 1.3610 6 HeLa cells by calcium phosphate-DNA co-precipitation. The total amount of expression vector in each transfection was maintained at 10 mg by addition of dEB, an SV40-based expression vector lacking transcription factor coding sequences (Bosselut et al., 1990) . A b-actin control promoter plasmid (pAGb.B0, 1 mg) was included in all transfections as an internal control for transfection eciency. After 48 h, primer extension analysis of the total RNA was performed and quanti®ed as previously described (McCracken et al., 1994) .
Gel mobility shift assays
Protein (7 mg) from nuclear extracts (Leung et al., 1993) of CEM, Jurkat, SW620, Colo201, and HeLa cells was added to a reaction mix to give ®nal (15 ml) conditions of: 15 mM Hepes pH 7.9, 93 mM NaCl, 1 mM EDTA, 1.2 mM DTT, 10% glycerol, 2% sucrose, 0.002% (v/v) Nonidet P40, and 0.67 mg of poly(dG.dC).(dG.dC). Speci®c or non-speci®c oligo competitors were included in the mix where appropriate. After 5 min incubation at RT, a radioactively labelled oligo probe (10 fmol, 5610 4 c.p.m.) was added and the reaction was incubated for 20 min at RT, then analysed on a 0.256TBE-6% polyacrylamide gel and run for 2 h at 160 V. Radioactively labelled or nonradioactive ds oligos used as probes or competitiors were synthesized by a primer extension reaction (Gronostajski, 1986 ) using the Klenow fragment of E. coli DNA polymerase I in the presence of [a-
32 P]-dCTP (for radioactive probe synthesis) and 100 mM dATP, dGTP, TTP, (dCTP for nonradioactive probe synthesis) and annealed oligo (25 mer) and primer (10 mer). The sequence of the probe was as follows:
When puri®ed bacterially expressed proteins were assayed for DNA binding, 20 Zg of puri®ed Sox-4 protein was used.
Expression of the DNA binding domains
The TaqI fragment encoding DNA binding domain of human TCF-1, including exons 5, 6 and 7, was endrepaired with the Klenow fragment of DNA polymerase I and inserted into the SmaI site of pGEX-2T. The vector for expression of the DNA binding domain of LEF-1 as a GST fusion was constructed as previously described (Giese et al., 1991) . GST-TCF-1 and GST-LEF-1 were expressed and puri®ed by anity chromatography on glutathione agarose (Smith and Johnson, 1988) . The DNA binding domain of Sox-4 was puri®ed as described (van de Wetering et al., 1993) .
